Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorvardur R Halfdanarson

Showing results (141-150 of 213) with videos related to

Pageof 22
Sort By:
Endocrine-Related Cancer|January 7, 2026
Elevated Vasoactive Intestinal Peptide Concentrations Poorly Predict VIPomaJack Korleski, Luis E Ospina Velasquez, Joshua Bornhorst, et al.
Annals of Surgical Oncology|June 22, 2022
Safety and Outcomes of Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine TumorsHallbera Gudmundsdottir, Ron Pery, Rondell P Graham, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 7, 2025
The overarching prognostic role of tumor progression prior to cytoreductive hepatectomy in NETLMVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|January 20, 2021
Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancerCaleb J Smith, Tanios S Bekaii-Saab, Kathryn D Cook, et al.
Endocrine-Related Cancer|January 12, 2026
Cabozantinib for Advanced Grade 3 Neuroendocrine Tumors: Subgroup Analysis of the Phase 3 CABINET Trial (Alliance A021602)Jonathan R Strosberg, Tyler Zemla, Susan Geyer, et al.
Annals of Surgical Oncology|May 19, 2023
Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 PatientsHallbera Gudmundsdottir, Elizabeth B Habermann, Robert A Vierkant, et al.
Journal of Surgical Oncology|August 2, 2023
Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resectionChi Zhang, Hallbera Gudmundsdottir, Hiroaki Takahashi, et al.
Endocrine Pathology|November 3, 2025
Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating ChemotherapyLouis de Mestier, Thorvardur R Halfdanarson, Leonidas Apostolidis, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|January 26, 2022
Outcomes of pancreatectomy with portomesenteric venous resection and reconstruction for locally advanced pancreatic neuroendocrine neoplasmsHallbera Gudmundsdottir, Jennifer L Tomlinson, Rondell P Graham, et al.
Radiology. Imaging Cancer|July 21, 2023
A Review of Theranostics: Perspectives on Emerging Approaches and Clinical AdvancementsBrian J Burkett, David J Bartlett, Patrick W McGarrah, et al.
Pageof 22

Showing results (141-150 of 213) with videos related to

Sort By:
Pageof 22
Endocrine-Related Cancer|January 7, 2026
Elevated Vasoactive Intestinal Peptide Concentrations Poorly Predict VIPomaJack Korleski, Luis E Ospina Velasquez, Joshua Bornhorst, et al.
Annals of Surgical Oncology|June 22, 2022
Safety and Outcomes of Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine TumorsHallbera Gudmundsdottir, Ron Pery, Rondell P Graham, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 7, 2025
The overarching prognostic role of tumor progression prior to cytoreductive hepatectomy in NETLMVanja Podrascanin, Markus Ammann, Hallbera Gudmundsdottir, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|January 20, 2021
Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancerCaleb J Smith, Tanios S Bekaii-Saab, Kathryn D Cook, et al.
Endocrine-Related Cancer|January 12, 2026
Cabozantinib for Advanced Grade 3 Neuroendocrine Tumors: Subgroup Analysis of the Phase 3 CABINET Trial (Alliance A021602)Jonathan R Strosberg, Tyler Zemla, Susan Geyer, et al.
Annals of Surgical Oncology|May 19, 2023
Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 PatientsHallbera Gudmundsdottir, Elizabeth B Habermann, Robert A Vierkant, et al.
Journal of Surgical Oncology|August 2, 2023
Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resectionChi Zhang, Hallbera Gudmundsdottir, Hiroaki Takahashi, et al.
Endocrine Pathology|November 3, 2025
Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating ChemotherapyLouis de Mestier, Thorvardur R Halfdanarson, Leonidas Apostolidis, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|January 26, 2022
Outcomes of pancreatectomy with portomesenteric venous resection and reconstruction for locally advanced pancreatic neuroendocrine neoplasmsHallbera Gudmundsdottir, Jennifer L Tomlinson, Rondell P Graham, et al.
Radiology. Imaging Cancer|July 21, 2023
A Review of Theranostics: Perspectives on Emerging Approaches and Clinical AdvancementsBrian J Burkett, David J Bartlett, Patrick W McGarrah, et al.
Pageof 22